Snyder Mark Howard

Snyder Mark Howard is listed in filings as SVP at Halozyme Therapeutics, Inc.. This profile follows SEC Form 4 activity through Feb 24, 2026, including 21 public disclosures. Recent filings connect the profile to Halozyme Therapeutics, Inc. (HALO). The current snapshot covers public activity from Feb 21, 2025 to Feb 24, 2026. Reported amounts are shown as $267.2K to $514.9K. The page organizes purchases, sales, issuer links, reported share activity, and filing evidence for review as public disclosure data.